Trial reportSurgery today2025
Diagnostic accuracy of sentinel lymph node biopsy and wire localized clipped node biopsy after neoadjuvant chemotherapy in node-positive breast cancer.
Trial report in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03715686 (To Accurately Assess Lymph Node Response to Neoadjuvant Chemotherapy by Wire Localization of Clip-marked Axillary Lymph Nodes in Breast Cancer Patients), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
To Accurately Assess Lymph Node Response to Neoadjuvant Chemotherapy by Wire Localization of Clip-marked Axillary Lymph Nodes in Breast Cancer Patients
Who cites it
1 citing paper in PubMed.
- Optimizing axillary surgery for patients with clinically node-negative and node-positive breast cancer.Surgery today · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe optimal method for axillary staging in patients with initially node-positive breast cancer after NACT remains unclear.
methodsWe conducted a prospective, single-center trial to investigate the diagnostic performance of sentinel lymph node biopsy (SLNB) combined with wire localized lymph node biopsy (WLNB) of the clip-marked node as an axillary staging technique in patients with node-positive breast cancer after neoadjuvant chemotherapy (NACT).
resultsA total of 233 patients were enrolled, 208 of whom were included in the analysis. The IR of SLNB and WLNB alone were 63.0% and 70.7%, respectively. The identification rate (IR) of targeted axillary dissection (TAD) was 87.5%. The FNR of and NPV were 6.9% (95% confidence interval [CI]:2.0-11.8%) and 92.0% (95% CI 86.3-97.7%), respectively, for the TAD procedure, 17.1% (95% CI 8.2-25.6%) and 83.3% (95% CI:74.7-91.9%) for SLNB alone, and 6.7% (95% CI:1.5-12.0%) and 90.6% (95% CI:83.5-97.7%) for WLNB alone.
conclusionsThe diagnostic performance of TAD using wire localization was similar to that of the procedure performed using radioactive seed localization. (Clinical Trial Registration: NCT03715686).
Indexed as
Identifiers
39725764What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.